GlassScriptPhysician profile
John W Burnett
NPI 1760438972
$5,722.44
in general payments reported to CMS, 2019-2025
45 companies · $560 in 2025
The $560 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,423 · 2020: $1,043 · 2021: $1,258 · 2022: $365 · 2023: $538 · 2024: $537 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,634.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $774.78 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $724.82 | 2019-2024 | Otezla, Repatha, Prolia |
| Novo Nordisk INC | $652.55 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $515.25 | 2019-2022 | |
| Shield Therapeutics INC | $417.07 | 2023-2025 | Accrufer |
| Glaxosmithkline, LLC. | $364.20 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $290.79 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Eisai INC. | $253.99 | 2020-2021 | |
| Esperion Therapeutics, INC. | $214.05 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.44 | 2021-2025 | Jardiance |
| Pfizer INC. | $138.00 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.11 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $104.27 | 2020-2022 | |
| Daiichi Sankyo INC. | $95.52 | 2020-2023 | Injectafer |
| Abbvie INC. | $93.50 | 2019-2025 | Vraylar |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Burnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.